Amgen AMGN · NASDAQ
$432.49 -0.35% (-$1.54)
Summary
64 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 23 USD is left as net profit.
- It has raised its dividend 14 years in a row.
- It earns 14 USD a year on every 100 USD of invested capital.
- Revenue grew by 12% a year over the last 3 years.
What to watch
- For every 100 USD of shareholders' equity it carries 490 USD of debt.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 26.7 USD for 1 USD of yearly profit. Over the last five years it was 24.8 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 7.6% a year over 5 years. Over the last 3 years it grew by 12% a year. For the next fiscal year analysts expect revenue to grow by 6.1%. Earnings per share grew by 5.5% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 27 USD
- Research and development 20 USD
- Sales and administration 19 USD
- Taxes and other 10 USD
- Net profit 23 USD
Net profit, industry median (Drug Manufacturers - General) 14 USD
Out of every 100 USD of revenue, 23 USD is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 5.6 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, stretched- Yield
- 2.30%
- Paid out of profit
- 61%
- Raised in a row
- 14 years
You receive $9.94 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 22
- Hold 16
- Sell 3
Today's price within the analysts' price targets
The average target of $402.21 is 7.0% below today's price. 54% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Other Products 21%
- Prolia 12%
- Repatha 8.5%
- Otezla 6.4%
- ENBREL 6.3%
- Other 46%
By region
- UNITED STATES 72%
- Non-US 28%
Other Products brings in 21% of revenue. Prolia grew fastest, by 8.0% a year.
Segments in detail